CRISPR/Cas13-mediated RNA Targeting Therapy for the Treatment of nAMD Investigator-Initiated Trial (SIGHT-I)

Condition:   Neovascular Age-related Macular Degeneration(nAMD) Intervention:   Genetic: HG202 Sponsors:   HuidaGene Therapeutics Co., Ltd.;   Tianjin Medical University Eye Hospital;   Eye & ENT Hospital of Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials